

116TH CONGRESS
1ST SESSION

H. R. 3443

To clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

JUNE 24, 2019

Ms. DEGETTE (for herself, Mr. LATTA, Mrs. DINGELL, and Mr. GUTHRIE) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

4 (a) SHORT TITLE.—This Act may be cited as the
5 “Over-the-Counter Monograph Safety, Innovation, and
6 Reform Act of 2019”.

7 (b) TABLE OF CONTENTS.—The table of contents for
8 this Act is as follows:

Sec. 1. Short title; table of contents.

TITLE I—OTC DRUG REVIEW

- Sec. 1001. Regulation of certain nonprescription drugs that are marketed without an approved drug application.
- Sec. 1002. Misbranding.
- Sec. 1003. Drugs excluded from the over-the-counter drug review.
- Sec. 1004. Treatment of Sunscreen Innovation Act.
- Sec. 1005. Annual update to Congress on appropriate pediatric indication for certain OTC cough and cold drugs.
- Sec. 1006. Technical corrections.

TITLE II—USER FEES

- Sec. 2001. Short title; finding.
- Sec. 2002. Fees relating to over-the-counter drugs.

1 TITLE I—OTC DRUG REVIEW**2 SEC. 1001. REGULATION OF CERTAIN NONPRESCRIPTION****3 DRUGS THAT ARE MARKETED WITHOUT AN
4 APPROVED DRUG APPLICATION.**

5 (a) IN GENERAL.—Chapter V of the Federal Food,
6 Drug, and Cosmetic Act is amended by inserting after sec-
7 tion 505F of such Act (21 U.S.C. 355g) the following:

**8 “SEC. 505G. REGULATION OF CERTAIN NONPRESCRIPTION
9 DRUGS THAT ARE MARKETED WITHOUT AN
10 APPROVED DRUG APPLICATION.**

11 “(a) NONPRESCRIPTION DRUGS MARKETED WITH-
12 OUT AN APPROVED APPLICATION.—Nonprescription
13 drugs marketed without an approved drug application
14 under section 505, as of the date of the enactment of this
15 section, shall be treated in accordance with this sub-
16 section.

17 “(1) DRUGS SUBJECT TO A FINAL MONOGRAPH;
18 CATEGORY I DRUGS SUBJECT TO A TENTATIVE
19 FINAL MONOGRAPH.—A drug is deemed to be gen-

1 erally recognized as safe and effective under section
2 201(p)(1), not a new drug under section 201(p), and
3 not subject to section 503(b)(1), if—

4 “(A) the drug is—

5 “(i) in conformity with the require-
6 ments for nonprescription use of a final
7 monograph issued under part 330 of title
8 21, Code of Federal Regulations (except as
9 provided in paragraph (2)), the general re-
10 quirements for nonprescription drugs, and
11 conditions or requirements under sub-
12 sections (b), (c), and (k); and

13 “(ii) except as permitted by an order
14 issued under subsection (b) or, in the case
15 of a minor change in the drug, in con-
16 formity with an order issued under sub-
17 section (c), in a dosage form that, imme-
18 diately prior to the date of the enactment
19 of this section, has been used to a material
20 extent and for a material time under sec-
21 tion 201(p)(2); or

22 “(B) the drug is—

23 “(i) classified in category I for safety
24 and effectiveness under a tentative final
25 monograph that is the most recently appli-

1 cable proposal or determination issued
2 under part 330 of title 21, Code of Federal
3 Regulations;

4 “(ii) in conformity with the proposed
5 requirements for nonprescription use of
6 such tentative final monograph, any appli-
7 cable subsequent determination by the Sec-
8 etary, the general requirements for non-
9 prescription drugs, and conditions or re-
10 quirements under subsections (b), (c), and
11 (k); and

12 “(iii) except as permitted by an order
13 issued under subsection (b) or, in the case
14 of a minor change in the drug, in con-
15 formity with an order issued under sub-
16 section (c), in a dosage form that, imme-
17 diately prior to the date of the enactment
18 of this section, has been used to a material
19 extent and for a material time under sec-
20 tion 201(p)(2).

21 “(2) TREATMENT OF SUNSCREEN DRUGS.—
22 With respect to sunscreen drugs subject to this sec-
23 tion, the applicable requirements in terms of con-
24 formity with a final monograph, for purposes of
25 paragraph (1)(A)(i), shall be the requirements speci-

1 fied in part 352 of title 21, Code of Federal Regula-
2 tions, as published on May 21, 1999, beginning on
3 page 27687 of volume 64 of the Federal Register,
4 except that the applicable requirements governing ef-
5 fectiveness and labeling shall be those specified in
6 section 201.327 of title 21, Code of Federal Regula-
7 tions.

8 “(3) CATEGORY III DRUGS SUBJECT TO A TEN-
9 TATIVE FINAL MONOGRAPH; CATEGORY I DRUGS
10 SUBJECT TO PROPOSED MONOGRAPH OR ADVANCE
11 NOTICE OF PROPOSED RULEMAKING.—A drug that
12 is not described in paragraph (1), (2), or (4) is not
13 required to be the subject of an application approved
14 under section 505, and is not subject to section
15 503(b)(1), if—

16 “(A) the drug is—

17 “(i) classified in category III for safe-
18 ty or effectiveness in the preamble of a
19 proposed rule establishing a tentative final
20 monograph that is the most recently appli-
21 cable proposal or determination for such
22 drug issued under part 330 of title 21,
23 Code of Federal Regulations;

24 “(ii) in conformity with—

1 “(I) the conditions of use, includ-
2 ing indication and dosage strength, if
3 any, described for such category III
4 drug in such preamble or in an appli-
5 cable subsequent proposed rule;

6 “(II) the proposed requirements
7 for drugs classified in such tentative
8 final monograph in category I in the
9 most recently proposed rule estab-
10 lishing requirements related to such
11 tentative final monograph and in any
12 final rule establishing requirements
13 that are applicable to the drug; and

14 “(III) the general requirements
15 for nonprescription drugs and condi-
16 tions or requirements under sub-
17 section (b) or (k); and

18 “(iii) in a dosage form that, imme-
19 diately prior to the date of the enactment
20 of this section, had been used to a material
21 extent and for a material time under sec-
22 tion 201(p)(2); or

23 “(B) the drug is—

24 “(i) classified in category I for safety
25 and effectiveness under a proposed mono-

1 graph or advance notice of proposed rule-
2 making that is the most recently applicable
3 proposal or determination for such drug
4 issued under part 330 of title 21, Code of
5 Federal Regulations;

6 “(ii) in conformity with the require-
7 ments for nonprescription use of such pro-
8 posed monograph or advance notice of pro-
9 posed rulemaking, any applicable subse-
10 quent determination by the Secretary, the
11 general requirements for nonprescription
12 drugs, and conditions or requirements
13 under subsection (b) or (k); and

14 “(iii) in a dosage form that, imme-
15 diately prior to the date of the enactment
16 of this section, has been used to a material
17 extent and for a material time under sec-
18 tion 201(p)(2).

19 “(4) CATEGORY II DRUGS DEEMED NEW
20 DRUGS.—A drug that is classified in category II for
21 safety or effectiveness under a tentative final mono-
22 graph or that is subject to a determination to be not
23 generally recognized as safe and effective in a pro-
24 posed rule that is the most recently applicable pro-
25 posal issued under part 330 of title 21, Code of Fed-

1 eral Regulations, shall be deemed to be a new drug
2 under section 201(p), misbranded under section
3 502(ee), and subject to the requirement for an ap-
4 proved new drug application under section 505 be-
5 ginning on the day that is 180 calendar days after
6 the date of the enactment of this section, unless, be-
7 fore such day, the Secretary determines that it is in
8 the interest of public health to extend the period
9 during which the drug may be marketed without
10 such an approved new drug application.

11 “(5) DRUGS NOT GRASE DEEMED NEW
12 DRUGS.—A drug that the Secretary has determined
13 not to be generally recognized as safe and effective
14 under section 201(p)(1) under a final determination
15 issued under part 330 of title 21, Code of Federal
16 Regulations, shall be deemed to be a new drug under
17 section 201(p), misbranded under section 502(ee),
18 and subject to the requirement for an approved new
19 drug application under section 505.

20 “(6) OTHER DRUGS DEEMED NEW DRUGS.—
21 Except as provided in subsection (m), a drug is
22 deemed to be a new drug under section 201(p) and
23 misbranded under section 502(ee) if the drug—

24 “(A) is not subject to section 503(b)(1);
25 and

1 “(B) is not described in paragraph (1),
2 (2), (3), (4), or (5), or subsection (b)(1)(B).

3 “(b) ADMINISTRATIVE ORDERS.—

4 “(1) IN GENERAL.—

5 “(A) DETERMINATION.—The Secretary
6 may, on the initiative of the Secretary or at the
7 request of one or more requestors, issue an ad-
8 ministrative order determining whether there
9 are conditions under which a specific drug, a
10 class of drugs, or a combination of drugs, is de-
11 termined to be—

12 “(i) not subject to section 503(b)(1);
13 and

14 “(ii) generally recognized as safe and
15 effective under section 201(p)(1).

16 “(B) EFFECT.—A drug or combination of
17 drugs shall be deemed to not require approval
18 under section 505 if such drug or combination
19 of drugs—

20 “(i) is determined by the Secretary to
21 meet the conditions specified in clauses (i)
22 and (ii) of subparagraph (A);

23 “(ii) is marketed in conformity with
24 an administrative order under this sub-
25 section;

1 “(iii) meets the general requirements
2 for nonprescription drugs; and

3 “(iv) meets the requirements under
4 subsections (c) and (k).

5 “(C) STANDARD.—The Secretary shall find
6 that a drug is not generally recognized as safe
7 and effective under section 201(p)(1) if—

8 “(i) the evidence shows that the drug
9 is not generally recognized as safe and ef-
10 fective under section 201(p)(1); or

11 “(ii) the evidence is inadequate to
12 show that the drug is generally recognized
13 as safe and effective under section
14 201(p)(1).

15 “(2) ADMINISTRATIVE ORDERS INITIATED BY
16 THE SECRETARY.—

17 “(A) IN GENERAL.—In issuing an adminis-
18 trative order under paragraph (1) upon the
19 Secretary’s initiative, the Secretary shall—

20 “(i) make reasonable efforts to notify
21 informally, not later than 2 business days
22 before the issuance of the proposed order,
23 the sponsors of drugs who have a listing in
24 effect under section 510(j) for the drugs or

1 combination of drugs that will be subject
2 to the administrative order;

3 “(ii) after any such reasonable efforts
4 of notification—

5 “(I) issue a proposed administra-
6 tive order by publishing it on the
7 website of the Food and Drug Admin-
8 istration and include in such order the
9 reasons for the issuance of such order;
10 and

11 “(II) publish a notice of avail-
12 ability of such proposed order in the
13 Federal Register;

14 “(iii) except as provided in subparagraph (B), provide for a public comment
15 period with respect to such proposed order
16 of not less than 45 calendar days; and

17 “(iv) if, after completion of the pro-
18 ceedings specified in clauses (i) through
19 (iii), the Secretary determines that it is ap-
20 propriate to issue a final administrative
21 order—

22 “(I) issue the final administrative
23 order, together with a detailed state-
24 ment of reasons, which order shall not

1 take effect until the time for requesting
2 judicial review under paragraph
3 (3)(D)(ii) has expired;

4 “(II) publish a notice of such
5 final administrative order in the Federal
6 Register;

7 “(III) afford requestors of drugs
8 that will be subject to such order the
9 opportunity for formal dispute resolution up to the level of the Director of
10 the Center for Drug Evaluation and
11 Research, which initially must be requested within 45 calendar days of
12 the issuance of the order, and, for subsequent levels of appeal, within 30 calendar days of the prior decision;
13 and

14 “(IV) except with respect to drugs described in paragraph (3)(B), upon completion of the formal dispute resolution procedure, inform the persons which sought such dispute resolution of their right to request a hearing.

1 “(B) EXCEPTIONS.—When issuing an ad-
2 ministrative order under paragraph (1) on the
3 Secretary’s initiative proposing to determine
4 that a drug described in subsection (a)(3) is not
5 generally recognized as safe and effective under
6 section 201(p)(1), the Secretary shall follow the
7 procedures in subparagraph (A), except that—

8 “(i) the proposed order shall include
9 notice of—

10 “(I) the general categories of
11 data the Secretary has determined
12 necessary to establish that the drug is
13 generally recognized as safe and effec-
14 tive under section 201(p)(1); and

15 “(II) the format for submissions
16 by interested persons;

17 “(ii) the Secretary shall provide for a
18 public comment period of no less than 180
19 calendar days with respect to such pro-
20 posed order, except when the Secretary de-
21 termines, for good cause, that a shorter pe-
22 riod is in the interest of public health; and

23 “(iii) any person who submits data in
24 such comment period shall include a cer-
25 tification that the person has submitted all

1 evidence created, obtained, or received by
2 that person that is both within the cat-
3 egories of data identified in the proposed
4 order and relevant to a determination as to
5 whether the drug is generally recognized as
6 safe and effective under section 201(p)(1).

7 “(3) HEARINGS; JUDICIAL REVIEW.—

8 “(A) IN GENERAL.—Only a person who
9 participated in each stage of formal dispute res-
10 olution under subclause (III) of paragraph
11 (2)(A)(iv) of an administrative order with re-
12 spect to a drug may request a hearing con-
13 cerning a final administrative order issued
14 under such paragraph with respect to such
15 drug. If a hearing is sought, such person must
16 submit a request for a hearing, which shall be
17 based solely on information in the administra-
18 tive record, to the Secretary not later than 30
19 calendar days after receiving notice of the final
20 decision of the formal dispute resolution proce-
21 dure.

22 “(B) NO HEARING REQUIRED WITH RE-
23 SPECT TO ORDERS RELATING TO CERTAIN
24 DRUGS.—

1 “(i) IN GENERAL.—The Secretary
2 shall not be required to provide notice and
3 an opportunity for a hearing pursuant to
4 paragraph (2)(A)(iv) if the final adminis-
5 trative order involved relates to a drug—

6 “(I) that is described in sub-
7 section (a)(3)(A); and

8 “(II) with respect to which no
9 human or non-human data studies rel-
10 evant to the safety or effectiveness of
11 such drug have been submitted to the
12 administrative record since the
13 issuance of the most recent tentative
14 final monograph relating to such
15 drug.

16 “(ii) HUMAN DATA STUDIES AND
17 NON-HUMAN DATA DEFINED.—In this sub-
18 paragraph:

19 “(I) The term ‘human data stud-
20 ies’ means clinical trials of safety or
21 effectiveness (including actual use
22 studies), pharmacokinetics studies, or
23 bioavailability studies.

24 “(II) The term ‘non-human data’
25 means data from testing other than

1 with human subjects which provides
2 information concerning safety or ef-
3 fectiveness.

4 “(C) HEARING PROCEDURES.—

5 “(i) DENIAL OF REQUEST FOR HEAR-
6 ING.—If the Secretary determines that in-
7 formation submitted in a request for a
8 hearing under subparagraph (A) with re-
9 spect to a final administrative order issued
10 under paragraph (2)(A)(iv) does not iden-
11 tify the existence of a genuine and sub-
12 stantial question of material fact, the Sec-
13 retary may deny such request. In making
14 such a determination, the Secretary may
15 consider only information and data that
16 are based on relevant and reliable scientific
17 principles and methodologies.

18 “(ii) SINGLE HEARING FOR MULTIPLE
19 RELATED REQUESTS.—If more than one
20 request for a hearing is submitted with re-
21 spect to the same administrative order
22 under subparagraph (A), the Secretary
23 may direct that a single hearing be con-
24 ducted in which all persons whose hearing
25 requests were granted may participate.

1 “(iii) PRESIDING OFFICER.—The pre-
2 siding officer of a hearing requested under
3 subparagraph (A) shall—

4 “(I) be designated by the Sec-
5 retary;

6 “(II) not be an employee of the
7 Center for Drug Evaluation and Re-
8 search; and

9 “(III) not have been previously
10 involved in the development of the ad-
11 ministrative order involved or pro-
12 ceedings relating to that administra-
13 tive order.

14 “(iv) RIGHTS OF PARTIES TO HEAR-
15 ING.—The parties to a hearing requested
16 under subparagraph (A) shall have the
17 right to present testimony, including testi-
18 mony of expert witnesses, and to cross-ex-
19 amine witnesses presented by other parties.
20 Where appropriate, the presiding officer
21 may require that cross-examination by par-
22 ties representing substantially the same in-
23 terests be consolidated to promote effi-
24 ciency and avoid duplication.

25 “(v) FINAL DECISION.—

1 “(I) At the conclusion of a hear-
2 ing requested under subparagraph
3 (A), the presiding officer of the hear-
4 ing shall issue a decision containing
5 findings of fact and conclusions of
6 law. The decision of the presiding offi-
7 cer shall be final.

8 “(II) The final decision may not
9 take effect until the period under sub-
10 paragraph (D)(ii) for submitting a re-
11 quest for judicial review of such deci-
12 sion expires.

13 “(D) JUDICIAL REVIEW OF FINAL ADMIN-
14 ISTRATIVE ORDER.—

15 “(i) IN GENERAL.—The procedures
16 described in section 505(h) shall apply
17 with respect to judicial review of final ad-
18 ministrative orders issued under this sub-
19 section in the same manner and to the
20 same extent as such section applies to an
21 order described in such section except that
22 the judicial review shall be taken by filing
23 in an appropriate district court of the
24 United States in lieu of the appellate
25 courts specified in such section.

1 “(ii) PERIOD TO SUBMIT A REQUEST
2 FOR JUDICIAL REVIEW.—A person eligible
3 to request a hearing under this paragraph
4 and seeking judicial review of a final ad-
5 ministrative order issued under this sub-
6 section shall file such request for judicial
7 review not later than 60 calendar days
8 after the latest of—

9 “(I) the date on which notice of
10 such order is published;

11 “(II) the date on which a hearing
12 with respect to such order is denied
13 under subparagraph (B) or (C)(i);

14 “(III) the date on which a final
15 decision is made following a hearing
16 under subparagraph (C)(v); or

17 “(IV) if no hearing is requested,
18 the date on which the time for re-
19 questing a hearing expires.

20 “(4) EXPEDITED PROCEDURE WITH RESPECT
21 TO ADMINISTRATIVE ORDERS INITIATED BY THE
22 SECRETARY.—

23 “(A) IMMINENT HAZARD TO THE PUBLIC
24 HEALTH.—

1 “(i) IN GENERAL.—In the case of a
2 determination by the Secretary that a
3 drug, class of drugs, or combination of
4 drugs subject to this section poses an im-
5 minent hazard to the public health, the
6 Secretary, after first making reasonable ef-
7 forts to notify, not later than 48 hours be-
8 fore issuance of such order under this sub-
9 paragraph, sponsors who have a listing in
10 effect under section 510(j) for such drug
11 or combination of drugs—

12 “(I) may issue an interim final
13 administrative order for such drug,
14 class of drugs, or combination of
15 drugs under paragraph (1), together
16 with a detailed statement of the rea-
17 sons for such order;

18 “(II) shall publish in the Federal
19 Register a notice of availability of any
20 such order; and

21 “(III) shall provide for a public
22 comment period of at least 45 cal-
23 endar days with respect to such in-
24 terim final order.

1 “(ii) NONDELEGATION.—The Secretary may not delegate the authority to issue an interim final administrative order under this subparagraph.

5 “(B) SAFETY LABELING CHANGES.—

6 “(i) IN GENERAL.—In the case of a determination by the Secretary that a change in the labeling of a drug, class of drugs, or combination of drugs subject to this section is reasonably expected to mitigate a significant or unreasonable risk of a serious adverse event associated with use of the drug, the Secretary may—

14 “(I) make reasonable efforts to notify informally, not later than 48 hours before the issuance of the interim final order, the sponsors of drugs who have a listing in effect under section 510(j) for such drug or combination of drugs;

21 “(II) after reasonable efforts of notification, issue an interim final administrative order in accordance with paragraph (1) to require such change,

1 together with a detailed statement of
2 the reasons for such order;

3 “(III) publish in the Federal
4 Register a notice of availability of
5 such order; and

6 “(IV) provide for a public com-
7 ment period of at least 45 calendar
8 days with respect to such interim final
9 order.

10 “(ii) CONTENT OF ORDER.—An in-
11 terim final order issued under this sub-
12 paragraph with respect to the labeling of a
13 drug may provide for new warnings and
14 other information required for safe use of
15 the drug.

16 “(C) EFFECTIVE DATE.—An order under
17 subparagraph (A) or (B) shall take effect on a
18 date specified by the Secretary.

19 “(D) FINAL ORDER.—After the completion
20 of the proceedings in subparagraph (A) or (B),
21 the Secretary shall—

22 “(i) issue a final order in accordance
23 with paragraph (1);

1 “(ii) publish a notice of availability of
2 such final administrative order in the Fed-
3 eral Register; and

4 “(iii) afford sponsors of such drugs
5 that will be subject to such an order the
6 opportunity for formal dispute resolution
7 up to the level of the Director of the Cen-
8 ter for Drug Evaluation and Research,
9 which must initially be within 45 calendar
10 days of the issuance of the order, and for
11 subsequent levels of appeal, within 30 cal-
12 endar days of the prior decision.

13 “(E) HEARINGS.—A sponsor of a drug
14 subject to a final order issued under subpara-
15 graph (D) and that participated in each stage
16 of formal dispute resolution under clause (iii) of
17 such subparagraph may request a hearing on
18 such order. The provisions of subparagraphs
19 (A), (B), and (C) of paragraph (3), other than
20 paragraph (3)(C)(v)(II), shall apply with re-
21 spect to a hearing on such order in the same
22 manner and to the same extent as such provi-
23 sions apply with respect to a hearing on an ad-
24 ministrative order issued under paragraph
25 (2)(A)(iv).

1 “(F) TIMING.—

2 “(i) FINAL ORDER AND HEARING.—

3 The Secretary shall—

4 “(I) not later than 6 months
5 after the date on which the comment
6 period closes under subparagraph (A)
7 or (B), issue a final order in accord-
8 ance with paragraph (1); and

9 “(II) not later than 12 months
10 after the date on which such final
11 order is issued, complete any hearing
12 under subparagraph (E).

13 “(ii) DISPUTE RESOLUTION RE-
14 QUEST.—The Secretary shall specify in an
15 interim final order issued under subpara-
16 graph (A) or (B) such shorter periods for
17 requesting dispute resolution under sub-
18 paragraph (D)(iii) as are necessary to
19 meet the requirements of this subpara-
20 graph.

21 “(G) JUDICIAL REVIEW.—A final order
22 issued pursuant to subparagraph (F) shall be
23 subject to judicial review in accordance with
24 paragraph (3)(D).

1 “(5) ADMINISTRATIVE ORDER INITIATED AT
2 THE REQUEST OF A REQUESTOR.—

3 “(A) IN GENERAL.—In issuing an adminis-
4 trative order under paragraph (1) at the re-
5 quest of a requestor with respect to certain
6 drugs, classes of drugs, or combinations of
7 drugs—

8 “(i) the Secretary shall, after receiv-
9 ing a request under this subparagraph, de-
10 termine whether the request is sufficiently
11 complete and formatted to permit a sub-
12 stantive review;

13 “(ii) if the Secretary determines that
14 the request is sufficiently complete and for-
15 matted to permit a substantive review, the
16 Secretary shall—

17 “(I) file the request; and

18 “(II) initiate proceedings with re-
19 spect to issuing an administrative
20 order in accordance with paragraphs
21 (2) and (3); and

22 “(iii) except as provided in paragraph
23 (6), if the Secretary determines that a re-
24 quest does not meet the requirements for
25 filing or is not sufficiently complete and

1 formatted to permit a substantive review,
2 the requestor may demand that the request
3 be filed over protest, and the Secretary
4 shall initiate proceedings to review the re-
5 quest in accordance with paragraph (2)(A).

6 “(B) REQUEST TO INITIATE PRO-
7 CEEDINGS.—

8 “(i) IN GENERAL.—A requestor seek-
9 ing an administrative order under para-
10 graph (1) with respect to certain drugs,
11 classes of drugs, or combinations of drugs,
12 shall submit to the Secretary a request to
13 initiate proceedings for such order in the
14 form and manner as specified by the Sec-
15 etary. Such requestor may submit a re-
16 quest under this subparagraph for the
17 issuance of an administrative order—

18 “(I) determining whether a drug
19 is generally recognized as safe and ef-
20 fective under section 201(p)(1), ex-
21 empt from section 503(b)(1), and not
22 required to be the subject of an ap-
23 proved application under section 505;
24 or

1 “(II) determining whether a
2 change to a condition of use of a drug
3 is generally recognized as safe and ef-
4 fective under section 201(p)(1), ex-
5 empt from section 503(b)(1), and not
6 required to be the subject of an ap-
7 proved application under section 505,
8 if, absent such a changed condition of
9 use, such drug is—

10 “(aa) generally recognized
11 as safe and effective under sec-
12 tion 201(p)(1) in accordance with
13 subsection (a)(1), (a)(2), or an
14 order under this subsection; or

15 “(bb) subject to subsection
16 (a)(3), but only if such requestor
17 initiates such request in conjunc-
18 tion with a request for the Sec-
19 retary to determine whether such
20 drug is generally recognized as
21 safe and effective under section
22 201(p)(1), which is filed by the
23 Secretary under subparagraph
24 (A)(ii).

1 “(ii) EXCEPTION.—The Secretary is
2 not required to complete review of a re-
3 quest for a change described in clause
4 (i)(II) if the Secretary determines that
5 there is an inadequate basis to find the
6 drug is generally recognized as safe and ef-
7 fective under section 201(p)(1) under para-
8 graph (1) and issues a final order an-
9 nouncing that determination.

10 “(iii) WITHDRAWAL.—The requestor
11 may withdraw a request under this para-
12 graph, according to the procedures set
13 forth pursuant to subsection (d)(2)(B).
14 Notwithstanding any other provision of
15 this section, if such request is withdrawn,
16 the Secretary may cease proceedings under
17 this subparagraph.

18 “(C) EXCLUSIVITY.—

19 “(i) IN GENERAL.—A final adminis-
20 trative order issued in response to a re-
21 quest under this section shall have the ef-
22 fect of authorizing solely the order re-
23 questor (or the licensees, assignees, or suc-
24 cessors in interest of such requestor with
25 respect to the subject of such order), for a

1 period of 18 months following the effective
2 date of such final order and beginning on
3 the date the requestor may lawfully market
4 such drugs pursuant to the order, to mar-
5 ket drugs—

6 “(I) incorporating changes de-
7 scribed in clause (ii); and

8 “(II) subject to the limitations
9 under clause (iv).

10 “(ii) CHANGES DESCRIBED.—A
11 change described in this clause is a change
12 subject to an order specified in clause (i),
13 which—

14 “(I) provides for a drug to con-
15 tain an active ingredient (including
16 any ester or salt of the active ingre-
17 dient) not previously incorporated in a
18 drug described in clause (iii); or

19 “(II) provides for a change in the
20 conditions of use of a drug, for which
21 new human data studies conducted or
22 sponsored by the requestor (or for
23 which the requestor has an exclusive
24 right of reference) were essential to
25 the issuance of such order.

1 “(iii) DRUGS DESCRIBED.—The drugs
2 described in this clause are drugs—

3 “(I) specified in subsection
4 (a)(1), (a)(2), or (a)(3);

5 “(II) subject to a final order
6 issued under this section;

7 “(III) subject to a final sun-
8 screen order (as defined in section
9 586(2)(A)); or

10 “(IV) described in subsection
11 (m)(1), other than drugs subject to an
12 active enforcement action under chap-
13 ter III of this Act.

14 “(iv) LIMITATIONS ON EXCLU-
15 SIVITY.—

16 “(I) IN GENERAL.—Only one 18-
17 month period under this subparagraph
18 shall be granted, under each
19 order described in clause (i), with re-
20 spect to changes (to the drug subject
21 to such order) which are either—

22 “(aa) changes described in
23 clause (ii)(I), relating to active
24 ingredients; or

1 “(bb) changes described in
2 clause (ii)(II), relating to condi-
3 tions of use.

4 “(II) NO EXCLUSIVITY AL-
5 LOWED.—No exclusivity shall apply to
6 changes to a drug which are—

7 “(aa) the subject of a Tier 2
8 OTC monograph order request
9 (as defined in section 744L);

10 “(bb) safety-related changes,
11 as defined by the Secretary, or
12 any other changes the Secretary
13 considers necessary to assure
14 safe use; or

15 “(cc) changes related to
16 methods of testing safety or effi-
17 cacy.

18 “(v) NEW HUMAN DATA STUDIES DE-
19 FINED.—In this subparagraph, the term
20 ‘new human data studies’ means clinical
21 trials of safety or effectiveness (including
22 actual use studies), pharmacokinetics stud-
23 ies, or bioavailability studies, the results of
24 which—

1 “(I) have not been relied on by
2 the Secretary to support—

3 “(aa) a proposed or final de-
4 termination that a drug described
5 in subclause (I), (II), or (III) of
6 clause (iii) is generally recognized
7 as safe and effective under sec-
8 tion 201(p)(1); or

9 “(bb) approval of a drug
10 that was approved under section
11 505; and

12 “(II) do not duplicate the results
13 of another study that was relied on by
14 the Secretary to support—

15 “(aa) a proposed or final de-
16 termination that a drug described
17 in subclause (I), (II), or (III) of
18 clause (iii) is generally recognized
19 as safe and effective under sec-
20 tion 201(p)(1); or

21 “(bb) approval of a drug
22 that was approved under section
23 505.

24 “(6) INFORMATION REGARDING SAFE NON-
25 PRESCRIPTION MARKETING AND USE AS CONDITION

1 FOR FILING A GENERALLY RECOGNIZED AS SAFE
2 AND EFFECTIVE REQUEST.—

3 “(A) IN GENERAL.—In response to a re-
4 quest under this section that a drug described
5 in subparagraph (B) be generally recognized as
6 safe and effective, the Secretary—

7 “(i) may file such request, if the re-
8 quest includes information specified under
9 subparagraph (C) with respect to safe non-
10 prescription marketing and use of such
11 drug; or

12 “(ii) if the request fails to include in-
13 formation specified under subparagraph
14 (C), shall refuse to file such request and
15 require that nonprescription marketing of
16 the drug be pursuant to a new drug appli-
17 cation as described in subparagraph (D).

18 “(B) DRUG DESCRIBED.—A drug de-
19 scribed in this subparagraph is a nonprescrip-
20 tion drug which contains an active ingredient
21 not previously incorporated in a drug—

22 “(i) specified in subsection (a)(1),
23 (a)(2), or (a)(3);

24 “(ii) subject to a final order under
25 this section; or

1 “(iii) subject to a final sunscreen
2 order (as defined in section 586(2)(A)).

3 “(C) INFORMATION DEMONSTRATING
4 PRIMA FACIE SAFE NONPRESCRIPTION MAR-
5 KETING AND USE.—Information specified in
6 this subparagraph, with respect to a request de-
7 scribed in subparagraph (A)(i), is—

8 “(i) information sufficient for a prima
9 facie demonstration that the drug subject
10 to such request has a verifiable history of
11 being marketed and safely used by con-
12 sumers in the United States as a non-
13 prescription drug under comparable condi-
14 tions of use;

15 “(ii) if the drug has not been pre-
16 viously marketed in the United States as a
17 nonprescription drug, information suffi-
18 cient for a prima facie demonstration that
19 the drug was marketed and safely used
20 under comparable conditions of marketing
21 and use in a country listed in section
22 802(b)(1)(A) or designated by the Sec-
23 retary in accordance with section
24 802(b)(1)(B)—

1 “(I) for such period as needed to
2 provide reasonable assurances con-
3 cerning the safe nonprescription use
4 of the drug; and

5 “(II) during such time was sub-
6 ject to sufficient monitoring by a reg-
7 ulatory body considered acceptable by
8 the Secretary for such monitoring
9 purposes, including for adverse events
10 associated with nonprescription use of
11 the drug; or

12 “(iii) if the Secretary determines that
13 information described in clause (i) or (ii) is
14 not needed to provide a *prima facie* dem-
15 onstration that the drug can be safely mar-
16 keted and used as a nonprescription drug,
17 such other information the Secretary deter-
18 mines is sufficient for such purposes.

19 “(D) MARKETING PURSUANT TO NEW
20 DRUG APPLICATION.—In the case of a request
21 described in subparagraph (A)(ii), the drug
22 subject to such request may be resubmitted for
23 filing only if—

24 “(i) the drug is marketed as a non-
25 prescription drug, under conditions of use

1 comparable to the conditions specified in
2 the request, for such period as the Sec-
3 retary determines appropriate (not to ex-
4 ceed 5 consecutive years) pursuant to an
5 application approved under section 505;
6 and

7 “(ii) during such period, 1,000,000
8 retail packages of the drug, or an equiva-
9 lent quantity as determined by the Sec-
10 retary, were distributed for retail sale, as
11 determined in such manner as the Sec-
12 retary finds appropriate.

13 “(E) RULE OF APPLICATION.—Except in
14 the case of a request involving a drug described
15 in section 586(9), as in effect on January 1,
16 2017, if the Secretary refuses to file a request
17 under this paragraph, the requestor may not
18 file such request over protest under paragraph
19 (5)(A)(iii).

20 “(7) PACKAGING.—An administrative order
21 issued under paragraph (2), (4)(A), or (5) may in-
22 clude requirements for the packaging of a drug to
23 encourage use in accordance with labeling. Such re-
24 quirements may include unit dose packaging, re-
25 quirements for products intended for use by pedi-

1 atric populations, requirements to reduce risk of
2 harm from unsupervised ingestion, and other appropriate requirements. This paragraph does not authorize the Food and Drug Administration to require standards or testing procedures as described in part 1700 of title 16, Code of Federal Regulations.

7 “(8) FINAL AND TENTATIVE FINAL MONO-
8 GRAPHS FOR CATEGORY I DRUGS DEEMED FINAL
9 ADMINISTRATIVE ORDERS.—

10 “(A) IN GENERAL.—A final monograph or
11 tentative final monograph described in subparagraph (B) shall be deemed to be a final administrative order under this subsection and may
12 be amended, revoked, or otherwise modified in
13 accordance with the procedures of this sub-
14 section.

17 “(B) MONOGRAPHS DESCRIBED.—For purposes of subparagraph (A), a final monograph or tentative final monograph is described in this
18 subparagraph if it—

21 “(i) establishes conditions of use for a
22 drug described in paragraph (1) or (2) of
23 subsection (a); and

24 “(ii) represents the most recently promulgated version of such conditions, in-

1 cluding as modified, in whole or in part, by
2 any proposed or final rule.

3 “(C) DEEMED ORDERS INCLUDE HARMONIZING TECHNICAL AMENDMENTS.—The
4 deemed establishment of a final administrative
5 order under subparagraph (A) shall be construed to include any technical amendments to
6 such order as the Secretary determines necessary to ensure that such order is appropriately harmonized, in terms of terminology or
7 cross-references, with the applicable provisions
8 of this Act (and regulations thereunder) and
9 any other orders issued under this section.

10 “(c) PROCEDURE FOR MINOR CHANGES.—

11 “(1) IN GENERAL.—Minor changes in the dosage form of a drug that is described in paragraph
12 (1) or (2) of subsection (a) or the subject of an
13 order issued under subsection (b) may be made by
14 a requestor without the issuance of an order under
15 subsection (b) if—

16 “(A) the requestor maintains such information as is necessary to demonstrate that the
17 change—

18 “(i) will not affect the safety or effectiveness of the drug; and

1 “(ii) will not materially affect the ex-
2 tent of absorption or other exposure to the
3 active ingredient in comparison to a suit-
4 able reference product; and

5 “(B) the change is in conformity with the
6 requirements of an applicable administrative
7 order issued by the Secretary under paragraph
8 (3).

9 “(2) ADDITIONAL INFORMATION.—

10 “(A) ACCESS TO RECORDS.—A sponsor
11 shall submit records requested by the Secretary
12 relating to such a minor change under section
13 704(a)(4), within 15 business days of receiving
14 such a request, or such longer period as the
15 Secretary may provide.

16 “(B) INSUFFICIENT INFORMATION.—If the
17 Secretary determines that the information con-
18 tained in such records is not sufficient to dem-
19 onstrate that the change does not affect the
20 safety or effectiveness of the drug or materially
21 affect the extent of absorption or other expo-
22 sure to the active ingredient, the Secretary—

23 “(i) may so inform the sponsor of the
24 drug in writing; and

1 “(ii) if the Secretary so informs the
2 sponsor, shall provide the sponsor of the
3 drug with a reasonable opportunity to pro-
4 vide additional information.

5 “(C) FAILURE TO SUBMIT SUFFICIENT IN-
6 FORMATION.—If the sponsor fails to provide
7 such additional information within a time pre-
8 scribed by the Secretary, or if the Secretary de-
9 termines that such additional information does
10 not demonstrate that the change does not—

11 “(i) affect the safety or effectiveness
12 of the drug; or

13 “(ii) materially affect the extent of
14 absorption or other exposure to the active
15 ingredient in comparison to a suitable ref-
16 erence product,

17 the drug as modified is a new drug under sec-
18 tion 201(p) and shall be deemed to be mis-
19 branded under section 502(ee).

20 “(3) DETERMINING WHETHER A CHANGE WILL
21 AFFECT SAFETY OR EFFECTIVENESS.—

22 “(A) IN GENERAL.—The Secretary shall
23 issue one or more administrative orders speci-
24 fying requirements for determining whether a
25 minor change made by a sponsor pursuant to

1 this subsection will affect the safety or effectiveness of a drug or materially affect the extent of absorption or other exposure to an active ingredient in the drug in comparison to a suitable reference product, together with guidance for applying those orders to specific dosage forms.

7 “(B) STANDARD PRACTICES.—The orders
8 and guidance issued by the Secretary under
9 subparagraph (A) shall take into account relevant public standards and standard practices
10 for evaluating the quality of drugs, and may
11 take into account the special needs of populations, including children.

14 “(d) CONFIDENTIALITY OF INFORMATION SUBMITTED TO THE SECRETARY.—

16 “(1) IN GENERAL.—Subject to paragraph (2), any information, including reports of testing conducted on the drug or drugs involved, that is submitted by a requestor in connection with proceedings on an order under this section (including any minor change under subsection (c)) and is a trade secret or confidential information subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code, shall not be

1 disclosed to the public unless the requestor consents
2 to that disclosure.

3 “(2) PUBLIC AVAILABILITY.—

4 “(A) IN GENERAL.—Except as provided in
5 subparagraph (B), the Secretary shall—

6 “(i) make any information submitted
7 by a requestor in support of a request
8 under subsection (b)(5)(A) available to the
9 public not later than the date on which the
10 proposed order is issued; and

11 “(ii) make any information submitted
12 by any other person with respect to an
13 order requested (or initiated by the Sec-
14 retary) under subsection (b), available to
15 the public upon such submission.

16 “(B) LIMITATIONS ON PUBLIC AVAIL-
17 ABILITY.—Information described in subpara-
18 graph (A) shall not be made public if—

19 “(i) the information pertains to phar-
20 maceutical quality information, unless such
21 information is necessary to establish stand-
22 ards under which a drug is generally rec-
23 ognized as safe and effective under section
24 201(p)(1);

1 “(ii) the information is submitted in a
2 requestor-initiated request, but the re-
3 questor withdraws such request, in accord-
4 ance with withdrawal procedures estab-
5 lished by the Secretary, before the Sec-
63 retary issues the proposed order;

7 “(iii) the Secretary requests and ob-
8 tains the information under subsection (c)
9 and such information is not submitted in
10 relation to an order under subsection (b);
11 or

12 “(iv) the information is of the type
13 contained in raw datasets.

14 “(e) UPDATES TO DRUG LISTING INFORMATION.—
15 A sponsor who makes a change to a drug subject to this
16 section shall submit updated drug listing information for
17 the drug in accordance with section 510(j) within 30 cal-
18 endar days of the date when the drug is first commercially
19 marketed, except that a sponsor who was the order re-
20 questor with respect to an order subject to subsection
21 (b)(5)(C) (or a licensee, assignee, or successor in interest
22 of such requestor) shall submit updated drug listing infor-
23 mation on or before the date when the drug is first com-
24 mercially marketed.

1 “(f) APPROVALS UNDER SECTION 505.—The provi-
2 sions of this section shall not be construed to preclude a
3 person from seeking or maintaining the approval of an ap-
4 plication for a drug under sections 505(b)(1), 505(b)(2),
5 and 505(j). A determination under this section that a drug
6 is not subject to section 503(b)(1), is generally recognized
7 as safe and effective under section 201(p)(1), and is not
8 a new drug under section 201(p) shall constitute a finding
9 that the drug is safe and effective that may be relied upon
10 for purposes of an application under section 505(b)(2), so
11 that the applicant shall be required to submit for purposes
12 of such application only information needed to support any
13 modification of the drug that is not covered by such deter-
14 mination under this section.

15 “(g) PUBLIC AVAILABILITY OF ADMINISTRATIVE OR-
16 DERS.—The Secretary shall establish, maintain, update
17 (as determined necessary by the Secretary but no less fre-
18 quently than annually), and make publicly available, with
19 respect to orders issued under this section—

20 “(1) a repository of each final order and in-
21 terim final order in effect, including the complete
22 text of the order; and

23 “(2) a listing of all orders proposed and under
24 development under subsection (b)(2), including—

1 “(A) a brief description of each such order;

2 and

3 “(B) the Secretary’s expectations, if re-
4 sources permit, for issuance of proposed orders
5 over a 3-year period.

6 “(h) DEVELOPMENT ADVICE TO SPONSORS OR RE-

7 QUESTORS.—The Secretary shall establish procedures
8 under which sponsors or requestors may meet with appro-
9 priate officials of the Food and Drug Administration to
10 obtain advice on the studies and other information nec-
11 essary to support submissions under this section and other
12 matters relevant to the regulation of nonprescription
13 drugs and the development of new nonprescription drugs
14 under this section.

15 “(i) PARTICIPATION OF MULTIPLE SPONSORS OR RE-
16 QUESTORS.—The Secretary shall establish procedures to
17 facilitate efficient participation by multiple sponsors or re-
18 questors in proceedings under this section, including provi-
19 sion for joint meetings with multiple sponsors or reques-
20 tors or with organizations nominated by sponsors or re-
21 questors to represent their interests in a proceeding.

22 “(j) ELECTRONIC FORMAT.—All submissions under
23 this section shall be in electronic format.

24 “(k) EFFECT ON EXISTING REGULATIONS Gov-
25 ERNING NONPRESCRIPTION DRUGS.—

1 “(1) REGULATIONS OF GENERAL APPLICA-
2 BILITY TO NONPRESCRIPTION DRUGS.—Except as
3 provided in this subsection, nothing in this section
4 supersedes regulations establishing general require-
5 ments for nonprescription drugs, including regula-
6 tions of general applicability contained in parts 201,
7 250, and 330 of title 21, Code of Federal Regula-
8 tions, or any successor regulations. The Secretary
9 shall establish or modify such regulations by means
10 of rulemaking in accordance with section 553 of title
11 5, United States Code.

12 “(2) REGULATIONS ESTABLISHING REQUIRE-
13 MENTS FOR SPECIFIC NONPRESCRIPTION DRUGS.—

14 “(A) The provisions of section 310.545 of
15 title 21, Code of Federal Regulations, as in ef-
16 fect on the day before the date of the enact-
17 ment of this section, shall be deemed to be a
18 final order under subsection (b).

19 “(B) Regulations in effect on the day be-
20 fore the date of the enactment of this section,
21 establishing requirements for specific non-
22 prescription drugs marketed pursuant to this
23 section (including such requirements in parts
24 201 and 250 of title 21, Code of Federal Regu-
25 lations), shall be deemed to be final orders

1 under subsection (b), only as they apply to
2 drugs—

3 “(i) subject to paragraph (1), (2), (3),
4 or (4) of subsection (a); or
5 “(ii) otherwise subject to an order
6 under this section.

7 “(3) WITHDRAWAL OF REGULATIONS.—The
8 Secretary shall withdraw regulations establishing
9 final monographs and the procedures governing the
10 over-the-counter drug review under part 330 and
11 other relevant parts of title 21, Code of Federal
12 Regulations (as in effect on the day before the date
13 of the enactment of this section), or make technical
14 changes to such regulations to ensure conformity
15 with appropriate terminology and cross references.
16 Notwithstanding subchapter II of chapter 5 of title
17 5, United States Code, any such withdrawal or tech-
18 nical changes shall be made without public notice
19 and comment and shall be effective upon publication
20 through notice in the Federal Register (or upon such
21 date as specified in such notice).

22 “(l) GUIDANCE.—The Secretary shall issue guidance
23 that specifies—

1 “(1) the procedures and principles for formal
2 meetings between the Secretary and sponsors or re-
3 questors for drugs subject to this section;

4 “(2) the format and content of data submis-
5 sions to the Secretary under this section;

6 “(3) the format of electronic submissions to the
7 Secretary under this section;

8 “(4) consolidated proceedings for appeal and
9 the procedures for such proceedings where appro-
10 priate; and

11 “(5) for minor changes in drugs, recommenda-
12 tions on how to comply with the requirements in or-
13 ders issued under subsection (c)(3).

14 “(m) RULE OF CONSTRUCTION.—

15 “(1) IN GENERAL.—This section shall not af-
16 fect the treatment or status of a nonprescription
17 drug—

18 “(A) that is marketed without an applica-
19 tion approved under section 505 as of the date
20 of the enactment of this section;

21 “(B) that is not subject to an order issued
22 under this section; and

23 “(C) to which paragraphs (1), (2), (3), (4),
24 or (5) of subsection (a) do not apply.

1 “(2) TREATMENT OF PRODUCTS PREVIOUSLY
2 FOUND TO BE SUBJECT TO TIME AND EXTENT RE-
3 QUIREMENTS.—

4 “(A) Notwithstanding subsection (a), a
5 drug described in subparagraph (B) may only
6 be lawfully marketed, without an application
7 approved under section 505, pursuant to an
8 order issued under this section.

9 “(B) A drug described in this subpara-
10 graph is a drug which, prior to the date of the
11 enactment of this section, the Secretary deter-
12 mined in a proposed or final rule to be ineligible
13 for review under the OTC drug review (as such
14 phrase ‘OTC drug review’ was used in section
15 330.14 of title 21, Code of Federal Regulations,
16 as in effect on the day before the date of the
17 enactment of this section).

18 “(3) PRESERVATION OF AUTHORITY.—

19 “(A) Nothing in paragraph (1) shall be
20 construed to preclude or limit the applicability
21 of any provision of this Act other than this sec-
22 tion.

23 “(B) Nothing in subsection (a) shall be
24 construed to prohibit the Secretary from issuing
25 an order under this section finding a drug to be

1 not generally recognized as safe and effective
2 under section 201(p)(1), as the Secretary deter-
3 mines appropriate.

4 “(n) INVESTIGATIONAL NEW DRUGS.—A drug is not
5 subject to this section if an exemption for investigational
6 use under section 505(i) is in effect for such drug.

7 “(o) INAPPLICABILITY OF PAPERWORK REDUCTION
8 ACT.—Chapter 35 of title 44, United States Code, shall
9 not apply to collections of information made under this
10 section.

11 “(p) INAPPLICABILITY OF NOTICE AND COMMENT
12 RULEMAKING AND OTHER REQUIREMENTS.—The re-
13 quirements of subsection (b) shall apply with respect to
14 orders issued under this section instead of the require-
15 ments of subchapter II of chapter 5 of title 5, United
16 States Code.

17 “(q) DEFINITIONS.—In this section:

18 “(1) The term ‘nonprescription drug’ refers to
19 a drug not subject to the requirements of section
20 503(b)(1).

21 “(2) The term ‘sponsor’ refers to any person
22 marketing, manufacturing, or processing a drug
23 that—

24 “(A) is listed pursuant to section 510(j);
25 and

1 “(B) is or will be subject to an administra-
2 tive order under this section of the Food and
3 Drug Administration.

4 “(3) The term ‘requestor’ refers to any person
5 or group of persons marketing, manufacturing, proc-
6 essing, or developing a drug.”.

7 (b) GAO STUDY.—Not later than 4 years after the
8 date of enactment of this Act, the Comptroller General
9 of the United States shall submit a study to the Com-
10 mittee on Energy and Commerce of the House of Rep-
11 resentatives and the Committee on Health, Education,
12 Labor, and Pensions of the Senate addressing the effec-
13 tiveness and overall impact of exclusivity under section
14 505G of the Federal Food, Drug, and Cosmetic Act, as
15 added by subsection (a), and section 586C of such Act
16 (21 U.S.C. 360fff–3), including the impact of such exclu-
17 sivity on consumer access. Such study shall include—

18 (1) an analysis of the impact of exclusivity
19 under such section 505G for nonprescription drug
20 products, including—

21 (A) the number of nonprescription drug
22 products that were granted exclusivity and the
23 indication for which the nonprescription drug
24 products were determined to be generally recog-
25 nized as safe and effective;

(B) whether the exclusivity for such drug products was granted for—

3 (i) a new active ingredient (including
4 any ester or salt of the active ingredient);
5 or

(C) whether, and to what extent, the exclusivity impacted the requestor's or sponsor's decision to develop the drug product;

1 (iv) the impact of such provision on
2 consumer access to nonprescription drug
3 products;

4 (v) the impact of such provision on
5 the prices of nonprescription drug prod-
6 ucts; and

14 (E) whether the administrative orders ini-
15 tiated by requestors under such section 505G
16 have been sufficient incentive to encourage in-
17 novation in the nonprescription drug market;
18 and

22 (A) the number of sunscreen ingredients
23 that were granted exclusivity and the specific
24 ingredient that was determined to be generally
25 recognized as safe and effective;

(B) whether, and to what extent, the exclusivity impacted the requestor's or sponsor's decision to develop the sunscreen ingredient;

4 (C) whether, and to what extent, the sun-
5 screen ingredient granted exclusivity had pre-
6 viously been available outside of the United
7 States;

11 (i) the resources used by the Food
12 and Drug Administration;

13 (ii) the impact of such provision on
14 innovation, as well as research and devel-
15 opment in the sunscreen market;

16 (iii) the impact of such provision on
17 competition in the sunscreen market;

18 (iv) the impact of such provision on
19 consumer access to sunscreen products;

20 (v) the impact of such provision
21 the prices of sunscreen products; and

22 (vi) whether the administrative orders
23 initiated by requestors under such section
24 505G have been utilized by sunscreen in-
25 gredient sponsors and whether such proc-

1 ess has been sufficient to encourage the
2 development of sunscreen ingredients that
3 would likely not be otherwise developed, or
4 developed in as timely a manner; and
5 (E) whether the administrative orders ini-
6 tiated by requestors under such section 586C
7 have been sufficient incentive to encourage in-
8 novation in the sunscreen market.

9 (c) CONFORMING AMENDMENT.—Section 751(d)(1)
10 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
11 379r(d)(1)) is amended—

12 (1) in the matter preceding subparagraph (A)—
13 (A) by striking “final regulation promul-
14 gated” and inserting “final order under section
15 505G”; and

16 (B) by striking “and not misbranded”; and
17 (2) in subparagraph (A), by striking “regula-
18 tion in effect” and inserting “regulation or order in
19 effect”.

20 **SEC. 1002. MISBRANDING.**

21 Section 502 of the Federal Food, Drug, and Cosmetic
22 Act (21 U.S.C. 352) is amended by adding at the end the
23 following:

24 “(ee) If it is a nonprescription drug that is subject
25 to section 505G, is not the subject of an application ap-

1 proved under section 505, and does not comply with the
2 requirements under section 505G.

3 “(ff) If it is a drug and it was manufactured, pre-
4 pared, propagated, compounded, or processed in a facility
5 for which fees have not been paid as required by section
6 744M.”.

7 **SEC. 1003. DRUGS EXCLUDED FROM THE OVER-THE-
8 COUNTER DRUG REVIEW.**

9 (a) IN GENERAL.—Nothing in this Act (or the
10 amendments made by this Act) shall apply to any non-
11 prescription drug (as defined in section 505G(q) of the
12 Federal Food, Drug, and Cosmetic Act, as added by sec-
13 tion 1001 of this Act) which was excluded by the Food
14 and Drug Administration from the Over-the-Counter
15 Drug Review in accordance with the paragraph numbered
16 25 on page 9466 of volume 37 of the Federal Register,
17 published on May 11, 1972.

18 (b) RULE OF CONSTRUCTION.—Nothing in this sec-
19 tion shall be construed to preclude or limit the applica-
20 bility of any other provision of the Federal Food, Drug,
21 and Cosmetic Act (21 U.S.C. 301 et seq.).

22 **SEC. 1004. TREATMENT OF SUNSCREEN INNOVATION ACT.**

23 (a) REVIEW OF NONPRESCRIPTION SUNSCREEN AC-
24 TIVE INGREDIENTS.—

1 Act, as added by section 1001 of this Act;

2 and

3 (ii) such order is deemed to have been
4 accepted for filing under subsection
5 (b)(6)(A)(i) of such section 505G.

6 (C) ELECTION NOT EXERCISED.—If a noti-
7 fication under subparagraph (A) is not received
8 by the Secretary of Health and Human Services
9 within 180 calendar days of the date of enact-
10 ment of this Act, the review of the proposed
11 sunscreen order described in subparagraph
12 (A)—

13 (i) shall continue under section 586C
14 of the Federal Food, Drug, and Cosmetic
15 Act (21 U.S.C. 360fff–3); and

16 (ii) shall not be eligible for review
17 under section 505G, added by section 1001
18 of this Act.

19 (2) DEFINITIONS.—In this subsection, the
20 terms “sponsor”, “nonprescription”, “sunscreen ac-
21 tive ingredient”, and “proposed sunscreen order”
22 have the meanings given to those terms in section
23 586 of the Federal Food, Drug, and Cosmetic Act
24 (21 U.S.C. 360fff).

25 (b) AMENDMENTS TO SUNSCREEN PROVISIONS.—

1 (1) FINAL SUNSCREEN ORDERS.—Paragraph
2 (3) of section 586C(e) of the Federal Food, Drug,
3 and Cosmetic Act (21 U.S.C. 360fff–3(e)) is amend-
4 ed to read as follows:

5 “(3) RELATIONSHIP TO ORDERS UNDER SEC-
6 TION 505G.—A final sunscreen order shall be deemed
7 to be a final order under section 505G.”.

8 (2) MEETINGS.—Paragraph (7) of section
9 586C(b) of the Federal Food, Drug, and Cosmetic
10 Act (21 U.S.C. 360fff–3(b)) is amended—

11 (A) by striking “A sponsor may request”
12 and inserting the following:

13 “(A) IN GENERAL.—A sponsor may re-
14 quest”; and

15 (B) by adding at the end the following:

16 “(B) CONFIDENTIAL MEETINGS.—A spon-
17 sor may request one or more confidential meet-
18 ings with respect to a proposed sunscreen order,
19 including a letter deemed to be a proposed sun-
20 screen order under paragraph (3), to discuss
21 matters relating to data requirements to sup-
22 port a general recognition of safety and effec-
23 tiveness involving confidential information and
24 public information related to such proposed
25 sunscreen order, as appropriate. The Secretary

1 shall convene a confidential meeting with such
2 sponsor in a reasonable time period. If a spon-
3 sor requests more than one confidential meeting
4 for the same proposed sunscreen order, the Sec-
5 retary may refuse to grant an additional con-
6 fidential meeting request if the Secretary deter-
7 mines that such additional confidential meeting
8 is not reasonably necessary for the sponsor to
9 advance its proposed sunscreen order, or if the
10 request for a confidential meeting fails to in-
11 clude sufficient information upon which to base
12 a substantive discussion. The Secretary shall
13 publish a post-meeting summary of each con-
14 fidential meeting under this subparagraph that
15 does not disclose confidential commercial infor-
16 mation or trade secrets. This subparagraph
17 does not authorize the disclosure of confidential
18 commercial information or trade secrets subject
19 to 552(b)(4) of title 5, United States Code, or
20 section 1905 of title 18, United States Code.”.

21 (3) EXCLUSIVITY.—Section 586C of the Fed-
22 eral Food, Drug, and Cosmetic Act (21 U.S.C.
23 360fff–3) is amended by adding at the end the fol-
24 lowing:

25 “(f) EXCLUSIVITY.—

1 “(1) IN GENERAL.—A final sunscreen order
2 shall have the effect of authorizing solely the order
3 requestor (or the licensees, assignees, or successors
4 in interest of such requestor with respect to the sub-
5 ject of such request and listed under paragraph (5))
6 for a period of 18 months, to market a sunscreen in-
7 gredient under this section incorporating changes
8 described in paragraph (2) subject to the limitations
9 under paragraph (4), beginning on the date the re-
10 questor (or any licensees, assignees, or successors in
11 interest of such requestor with respect to the subject
12 of such request and listed under paragraph (5)) may
13 lawfully market such sunscreen ingredient pursuant
14 to the order.

15 “(2) CHANGES DESCRIBED.—A change de-
16 scribed in this paragraph is a change subject to an
17 order specified in paragraph (1) that permits a sun-
18 screen to contain an active sunscreen ingredient not
19 previously incorporated in a marketed sunscreen list-
20 ed in paragraph (3).

21 “(3) MARKETED SUNSCREEN.—The marketed
22 sunscreen ingredients described in this paragraph
23 are sunscreen ingredients—

24 “(A) marketed in accordance with a final
25 monograph for sunscreen drug products set

1 forth at part 352 of title 21, Code of Federal
2 Regulations (as published at 64 Fed. Reg.
3 27687); or

4 “(B) marketed in accordance with a final
5 order issued under this section.

6 **“(4) LIMITATIONS ON EXCLUSIVITY.—**Only one
7 18-month period may be granted per ingredient
8 under paragraph (1).

9 **“(5) LISTING OF LICENSEES, ASSIGNEES, OR**
10 **SUCCESSORS IN INTEREST.—**Requestors shall submit
11 to the Secretary at the time when a drug subject to
12 such request is introduced or delivered for introduc-
13 tion into interstate commerce, a list of licensees, as-
14 signees, or successors in interest under paragraph
15 (1).”.

16 **(4) SUNSET PROVISION.—**Subchapter I of chap-
17 ter V of the Federal Food, Drug, and Cosmetic Act
18 (21 U.S.C. 360ffff et seq.) is amended by adding at
19 the end the following:

20 **“SEC. 586H. SUNSET.**

21 “This subchapter shall cease to be effective at the end
22 of fiscal year 2022.”.

23 **(5) TREATMENT OF FINAL SUNSCREEN**
24 **ORDER.—**The Federal Food, Drug, and Cosmetic

1 Act is amended by striking section 586E of such Act
2 (21 U.S.C. 360fff–5).

3 (c) TREATMENT OF AUTHORITY REGARDING FINAL-
4 IZATION OF SUNSCREEN MONOGRAPH.—

5 (1) IN GENERAL.—

6 (A) REVISION OF FINAL SUNSCREEN
7 ORDER.—Not later than November 26, 2019,
8 the Secretary of Health and Human Services
9 (referred to in this subsection as the “Sec-
10 retary”) shall amend and revise the final ad-
11 ministrative order concerning nonprescription
12 sunscreen (referred to in this subsection as the
13 “sunscreen order”) for which the content, prior
14 to the date of enactment of this Act, was rep-
15 resented by the final monograph for sunscreen
16 drug products set forth in part 352 of title 21,
17 Code of Federal Regulations (as in effect on
18 May 21, 1999).

19 (B) ISSUANCE OF REVISED SUNSCREEN
20 ORDER; EFFECTIVE DATE.—A revised sunscreen
21 order described in subparagraph (A) shall be—

22 (i) issued in accordance with the pro-
23 cedures described in section 505G(c)(2) of
24 the Federal Food, Drug, and Cosmetic
25 Act;

(2) REPORTS.—If a revised sunscreen order issued under paragraph (1) does not include provisions related to the effectiveness of various sun protection factor levels, and does not address all dosage forms known to the Secretary to be used in sunscreens marketed in the United States without a new drug application approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), the Secretary shall submit a report to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate on the rationale for omission of such provisions from such order, and a plan and timeline to compile any information necessary to address such provisions through such order.

24 (d) TREATMENT OF NON-SUNSCREEN TIME AND EX-

25 TENT APPLICATIONS.—

1 (1) IN GENERAL.—Any application described in
2 section 586F of the Federal Food, Drug, and Cos-
3 metic Act (21 U.S.C. 360fff–6) that was submitted
4 to the Secretary pursuant to section 330.14 of title
5 21, Code of Federal Regulations, as such provisions
6 were in effect immediately prior to the date of enact-
7 ment date of this Act, shall be extinguished as of
8 such date of enactment, subject to paragraph (2).

9 (2) ORDER REQUEST.—Nothing in paragraph
10 (1) precludes the submission of an order request
11 under section 505G(b) of the Federal Food, Drug,
12 and Cosmetic Act, as added by section 1001 of this
13 Act, with respect to a drug that was the subject of
14 an application extinguished under paragraph (1).

15 **SEC. 1005. ANNUAL UPDATE TO CONGRESS ON APPRO-**
16 **PRIATE PEDIATRIC INDICATION FOR CER-**
17 **TAIN OTC COUGH AND COLD DRUGS.**

18 (a) IN GENERAL.—Subject to subsection (c), the Sec-
19 retary of Health and Human Services shall, beginning not
20 later than 1 year after the date of enactment of this Act,
21 annually submit to the Committee on Energy and Com-
22 merce of the House of Representatives and the Committee
23 on Health, Education, Labor, and Pensions of the Senate
24 a letter describing the progress of the Food and Drug Ad-
25 ministration—

(1) in evaluating the cough and cold monograph described in subsection (b) with respect to children under age 6; and

9 (b) COUGH AND COLD MONOGRAPH DESCRIBED.—

10 The cough and cold monograph described in this sub-
11 section consists of the conditions under which nonprescrip-
12 tion drugs containing antitussive, expectorant, nasal de-
13 congestant, or antihistamine active ingredients (or com-
14 binations thereof) are generally recognized as safe and ef-
15 fective, as specified in part 341 of title 21, Code of Federal
16 Regulations (as in effect immediately prior to the date of
17 enactment of this Act), and included in an order deemed
18 to be established under section 505G(b) of the Federal
19 Food, Drug, and Cosmetic Act, as added by section 1001
20 of this Act.

21 (c) DURATION OF AUTHORITY.—The requirement
22 under subsection (a) shall terminate as of the date of a
23 letter submitted by the Secretary of Health and Human
24 Services pursuant to such subsection in which the Sec-
25 retary indicates that the Food and Drug Administration

1 has completed its evaluation and revised, in a final order,
2 as applicable, the cough and cold monograph as described
3 in subsection (a)(2).

4 **SEC. 1006. TECHNICAL CORRECTIONS.**

5 (a) IMPORTS AND EXPORTS.—Section
6 801(e)(4)(E)(iii) of the Federal Food, Drug, and Cosmetic
7 Act (21 U.S.C. 381(e)(4)(E)(iii)) is amended by striking
8 “subparagraph” each place such term appears and insert-
9 ing “paragraph”.

10 (b) FDA REAUTHORIZATION ACT OF 2017.—

11 (1) IN GENERAL.—Section 905(b)(4) of the
12 FDA Reauthorization Act of 2017 (Public Law 115–
13 52) is amended by striking “Section 744H(e)(2)(B)”
14 and inserting “Section 744H(f)(2)(B)”.

15 (2) EFFECTIVE DATE.—The amendment made
16 by paragraph (1) shall take effect as of the enact-
17 ment of the FDA Reauthorization Act of 2017
18 (Public Law 115–52).

19 **TITLE II—USER FEES**

20 **SEC. 2001. SHORT TITLE; FINDING.**

21 (a) SHORT TITLE.—This title may be cited as the
22 “Over-the-Counter Monograph User Fee Act of 2019”.

23 (b) FINDING.—The Congress finds that the fees au-
24 thorized by the amendments made in this title will be dedi-
25 cated to OTC monograph drug activities, as set forth in

1 the goals identified for purposes of part 10 of subchapter
2 C of chapter VII of the Federal Food, Drug, and Cosmetic
3 Act, in the letters from the Secretary of Health and
4 Human Services to the Chairman of the Committee on
5 Health, Education, Labor, and Pensions of the Senate and
6 the Chairman of the Committee on Energy and Commerce
7 of the House of Representatives, as set forth in the Con-
8 gressional Record.

9 **SEC. 2002. FEES RELATING TO OVER-THE-COUNTER DRUGS.**

10 Subchapter C of chapter VII of the Federal Food,
11 Drug, and Cosmetic Act (21 U.S.C. 379f et seq.) is
12 amended by inserting after part 9 the following:

13 **“PART 10—FEES RELATING TO OVER-THE-**
14 **COUNTER DRUGS**

15 **“SEC. 744L. DEFINITIONS.**

16 “In this part:

17 “(1) The term ‘affiliate’ means a business enti-
18 ty that has a relationship with a second business en-
19 tity if, directly or indirectly—

20 “(A) one business entity controls, or has
21 the power to control, the other business entity;

22 or

23 “(B) a third party controls, or has power
24 to control, both of the business entities.

1 “(2) The term ‘contract manufacturing organi-
2 zation facility’ means an OTC monograph drug facil-
3 ity where neither the owner of such manufacturing
4 facility nor any affiliate of such owner or facility
5 sells the OTC monograph drug produced at such fa-
6 cility directly to wholesalers, retailers, or consumers
7 in the United States.

8 “(3) The term ‘costs of resources allocated for
9 OTC monograph drug activities’ means the expenses
10 in connection with OTC monograph drug activities
11 for—

12 “(A) officers and employees of the Food
13 and Drug Administration, contractors of the
14 Food and Drug Administration, advisory com-
15 mittees, and costs related to such officers, em-
16 ployees, and committees and costs related to
17 contracts with such contractors;

18 “(B) management of information, and the
19 acquisition, maintenance, and repair of com-
20 puter resources;

21 “(C) leasing, maintenance, renovation, and
22 repair of facilities and acquisition, maintenance,
23 and repair of fixtures, furniture, scientific
24 equipment, and other necessary materials and
25 supplies; and

1 “(D) collecting fees under section 744M
2 and accounting for resources allocated for OTC
3 monograph drug activities.

4 “(4) The term ‘FDA establishment identifier’ is
5 the unique number automatically generated by Food
6 and Drug Administration’s Field Accomplishments
7 and Compliance Tracking System (FACTS) (or any
8 successor system).

9 “(5) The term ‘OTC monograph drug’ means a
10 nonprescription drug without an approved new drug
11 application which is governed by the provisions of
12 section 505G.

13 “(6) The term ‘OTC monograph drug activities’
14 means activities of the Secretary associated with
15 OTC monograph drugs and inspection of facilities
16 associated with such products, including the fol-
17 lowing activities:

18 “(A) The activities necessary for review
19 and evaluation of OTC monographs and OTC
20 monograph order requests, including—

21 “(i) orders proposing or finalizing ap-
22 plicable conditions of use for OTC mono-
23 graph drugs;

24 “(ii) orders affecting status regarding
25 general recognition of safety and effective-

1 ness of an OTC monograph ingredient or
2 combination of ingredients under specified
3 conditions of use;

4 “(iii) all OTC monograph drug devel-
5 opment and review activities, including
6 intra-agency collaboration;

7 “(iv) regulation and policy develop-
8 ment activities related to OTC monograph
9 drugs;

10 “(v) development of product standards
11 for products subject to review and evalua-
12 tion;

13 “(vi) meetings referred to in section
14 505G(i);

15 “(vii) review of labeling prior to
16 issuance of orders related to OTC mono-
17 graph drugs or conditions of use; and

18 “(viii) regulatory science activities re-
19 lated to OTC monograph drugs.

20 “(B) Inspections related to OTC mono-
21 graph drugs.

22 “(C) Monitoring of clinical and other re-
23 search conducted in connection with OTC
24 monograph drugs.

1 “(D) Safety activities with respect to OTC
2 monograph drugs, including—

3 “(i) collecting, developing, and review-
4 ing safety information on OTC monograph
5 drugs, including adverse event reports;

6 “(ii) developing and using improved
7 adverse event data-collection systems, in-
8 cluding information technology systems;
9 and

10 “(iii) developing and using improved
11 analytical tools to assess potential safety
12 risks, including access to external data-
13 bases.

14 “(E) Other activities necessary for imple-
15 mentation of section 505G.

16 “(7) The term ‘OTC monograph order request’
17 means a request for an order submitted under sec-
18 tion 505G(b)(5).

19 “(8) The term ‘Tier 1 OTC monograph order
20 request’ means any OTC monograph order request
21 not determined to be a Tier 2 OTC monograph
22 order request.

23 “(9)(A) The term ‘Tier 2 OTC monograph
24 order request’ means, subject to subparagraph (B),
25 an OTC monograph order request for—

1 “(i) the reordering of existing information
2 in the drug facts label of an OTC monograph
3 drug;

4 “(ii) the addition of information to the
5 other information section of the drug facts label
6 of an OTC monograph drug, as limited by sec-
7 tion 201.66(c)(7) of title 21, Code of Federal
8 Regulations (or any successor regulations);

9 “(iii) modification to the directions for use
10 section of the drug facts label of an OTC mono-
11 graph drug, if such changes conform to changes
12 made pursuant to section 505G(c)(3)(A);

13 “(iv) the standardization of the concentra-
14 tion or dose of a specific finalized ingredient
15 within a particular finalized monograph;

16 “(v) a change to ingredient nomenclature
17 to align with nomenclature of a standards-set-
18 ting organization; or

19 “(vi) addition of an interchangeable term
20 in accordance with section 330.1 of title 21,
21 Code of Federal Regulations (or any successor
22 regulations).

23 “(B) The Secretary may, based on program im-
24 plementation experience or other factors found ap-
25 propriate by the Secretary, characterize any OTC

1 monograph order request as a Tier 2 OTC mono-
2 graph order request (including recharacterizing a re-
3 quest from Tier 1 to Tier 2) and publish such deter-
4 mination in a proposed order issued pursuant to sec-
5 tion 505G.

6 “(10)(A) The term ‘OTC monograph drug facil-
7 ity’ means a foreign or domestic business or other
8 entity that—

9 “(i) is—

10 “(I) under one management, either di-
11 rect or indirect; and

12 “(II) at one geographic location or ad-
13 dress engaged in manufacturing or proc-
14 essing the finished dosage form of an OTC
15 monograph drug;

16 “(ii) includes a finished dosage form man-
17 ufacturer facility in a contractual relationship
18 with the sponsor of one or more OTC mono-
19 graph drugs to manufacture or process such
20 drugs; and

21 “(iii) does not include a business or other
22 entity whose only manufacturing or processing
23 activities are one or more of the following: pro-
24 duction of clinical research supplies, testing, or
25 placement of outer packaging on packages con-

1 taining multiple products, for such purposes as
2 creating multipacks, when each monograph
3 drug product contained within the overpack-
4 aging is already in a final packaged form prior
5 to placement in the outer overpackaging.

6 "(B) For purposes of subparagraph (A)(i)(II),
7 separate buildings or locations within close proximity
8 are considered to be at one geographic location or
9 address if the activities conducted in such buildings
10 or locations are—

11 "(i) closely related to the same business
12 enterprise;

13 "(ii) under the supervision of the same
14 local management; and

15 "(iii) under a single FDA establishment
16 identifier and capable of being inspected by the
17 Food and Drug Administration during a single
18 inspection.

19 "(C) If a business or other entity would meet
20 criteria specified in subparagraph (A), but for being
21 under multiple management, the business or other
22 entity is deemed to constitute multiple facilities, one
23 per management entity, for purposes of this para-
24 graph.

1 “(11) The term ‘OTC monograph drug meet-
2 ing’ means any meeting regarding the content of a
3 proposed OTC monograph order request.

4 “(12) The term ‘person’ includes an affiliate of
5 a person.

“(13) The terms ‘requestor’ and ‘sponsor’ have the meanings given such terms in section 505G.

10 “(a) TYPES OF FEES.—Beginning with fiscal year
11 2019, the Secretary shall assess and collect fees in accord-
12 ance with this section as follows:

13 “(1) FACILITY FEE.—

14 “(A) IN GENERAL.—Each person that
15 owns a facility identified as an OTC monograph
16 drug facility on December 31 of the fiscal year
17 or at any time during the preceding 12-month
18 period shall be assessed an annual fee for each
19 such facility as determined under subsection
20 (c).

21 “(B) EXCEPTIONS.—

22 “(i) A fee shall not be assessed under
23 subparagraph (A) if the identified OTC
24 monograph drug facility—

1 “(I) has ceased all activities re-
2 lated to OTC monograph drugs prior
3 to January 31, 2019, for the first pro-
4 gram year, and December 31 of the
5 fiscal year for subsequent fiscal years;
6 and

7 “(II) has updated its registration
8 to reflect such change under the re-
9 quirements for drug establishment
10 registration set forth in section 510.

11 “(ii) The amount of the fee for a con-
12 tract manufacturing organization facility
13 shall be equal to two-thirds of the amount
14 of the fee for an OTC monograph drug fa-
15 cility that is not a contract manufacturing
16 organization facility.

17 “(C) AMOUNT.—The amount of fees estab-
18 lished under subparagraph (A) shall be estab-
19 lished under subsection (c).

20 “(D) DUE DATE.—

21 “(i) FOR FIRST PROGRAM YEAR.—For
22 fiscal year 2019, the facility fees required
23 under subparagraph (A) shall be due 45
24 calendar days after publication of the Fed-

1 eral Register notice provided for under
2 subsection (c)(4)(A).

3 “(ii) SUBSEQUENT FISCAL YEARS.—
4 For each fiscal year after fiscal year 2019,
5 the facility fees required under subparagraph
6 (A) shall be due on the later of—

7 “(I) the first business day of
8 June of such year; or

9 “(II) the first business day after
10 the enactment of an appropriations
11 Act providing for the collection and
12 obligation of fees under this section
13 for such year.

14 “(2) OTC MONOGRAPH ORDER REQUEST
15 FEE.—

16 “(A) IN GENERAL.—Each person that submits
17 an OTC monograph order request shall be
18 subject to a fee for an OTC monograph order
19 request. The amount of such fee shall be—

20 “(i) for a Tier 1 OTC monograph
21 order request, \$500,000, adjusted for inflation
22 for the fiscal year (as determined
23 under subsection (c)(1)(B)); and

24 “(ii) for a Tier 2 OTC monograph
25 order request, \$100,000 adjusted for infla-

1 tion for the fiscal year (as determined
2 under subsection (c)(1)(B)).

3 “(B) DUE DATE.—The OTC monograph
4 order request fees required under subparagraph
5 (A) shall be due on the date of submission of
6 the OTC monograph order request.

7 “(C) EXCEPTION FOR CERTAIN SAFETY
8 CHANGES.—A person who is named as the re-
9 questor in an OTC monograph order shall not
10 be subject to a fee under subparagraph (A) if
11 the Secretary finds that the OTC monograph
12 order request seeks to change the drug facts la-
13 beling of an OTC monograph drug in a way
14 that would add to or strengthen—

15 “(i) a contraindication, warning, or
16 precaution;

17 “(ii) a statement about risk associated
18 with misuse or abuse; or

19 “(iii) an instruction about dosage and
20 administration that is intended to increase
21 the safe use of the OTC monograph drug.

22 “(D) REFUND OF FEE IF ORDER REQUEST
23 IS RECATEGORIZED AS A TIER 2 OTC MONO-
24 GRAPH ORDER REQUEST.—If the Secretary de-
25 termines that an OTC monograph request ini-

1 tially characterized as Tier 1 shall be re-charac-
2 terized as a Tier 2 OTC monograph order re-
3 quest, and the requestor has paid a Tier 1 fee
4 in accordance with subparagraph (A)(i), the
5 Secretary shall refund the requestor the dif-
6 ference between the Tier 1 and Tier 2 fees de-
7 termined under subparagraphs (A)(i) and
8 (A)(ii), respectively.

9 “(E) REFUND OF FEE IF ORDER REQUEST
10 REFUSED FOR FILING OR WITHDRAWN BEFORE
11 FILING.—The Secretary shall refund 75 percent
12 of the fee paid under subparagraph (B) for any
13 order request which is refused for filing or was
14 withdrawn before being accepted or refused for
15 filing.

16 “(F) FEES FOR ORDER REQUESTS PRE-
17 VIOUSLY REFUSED FOR FILING OR WITHDRAWN
18 BEFORE FILING.—An OTC monograph order
19 request that was submitted but was refused for
20 filing, or was withdrawn before being accepted
21 or refused for filing, shall be subject to the full
22 fee under subparagraph (A) upon being resub-
23 mitted or filed over protest.

24 “(G) REFUND OF FEE IF ORDER REQUEST
25 WITHDRAWN.—If an order request is withdrawn

1 after the order request was filed, the Secretary
2 may refund the fee or a portion of the fee if no
3 substantial work was performed on the order
4 request after the application was filed. The Sec-
5 retary shall have the sole discretion to refund a
6 fee or a portion of the fee under this subpara-
7 graph. A determination by the Secretary con-
8 cerning a refund under this subparagraph shall
9 not be reviewable.

10 “(3) REFUNDS.—

11 “(A) IN GENERAL.—Other than refunds
12 provided pursuant to any of subparagraphs (D)
13 through (G) of paragraph (2), the Secretary
14 shall not refund any fee paid under paragraph
15 (1) except as provided in subparagraph (B).

16 “(B) DISPUTES CONCERNING FEES.—To
17 qualify for the return of a fee claimed to have
18 been paid in error under paragraph (1) or (2),
19 a person shall submit to the Secretary a written
20 request justifying such return within 180 cal-
21 endar days after such fee was paid.

22 “(4) NOTICE.—Within the timeframe specified
23 in subsection (c), the Secretary shall publish in the
24 Federal Register the amount of the fees under para-
25 graph (1) for such fiscal year.

1 “(b) FEE REVENUE AMOUNTS.—

2 “(1) FISCAL YEAR 2019.—For fiscal year 2019,
3 fees under subsection (a)(1) shall be established to
4 generate a total facility fee revenue amount equal to
5 the sum of—

6 “(A) the annual base revenue for fiscal
7 year 2019 (as determined under paragraph
8 (3));

9 “(B) the dollar amount equal to the oper-
10 ating reserve adjustment for the fiscal year, if
11 applicable (as determined under subsection
12 (c)(2)); and

13 “(C) additional direct cost adjustments (as
14 determined under subsection (c)(3)).

15 “(2) SUBSEQUENT FISCAL YEARS.—For each of
16 the fiscal years 2020 through 2023, fees under sub-
17 section (a)(1) shall be established to generate a total
18 facility fee revenue amount equal to the sum of—

19 “(A) the annual base revenue for the fiscal
20 year (as determined under paragraph (3));

21 “(B) the dollar amount equal to the infla-
22 tion adjustment for the fiscal year (as deter-
23 mined under subsection (c)(1));

24 “(C) the dollar amount equal to the oper-
25 ating reserve adjustment for the fiscal year, if

1 applicable (as determined under subsection
2 (c)(2));

3 “(D) additional direct cost adjustments (as
4 determined under subsection (c)(3)); and

5 “(E) additional dollar amounts for each
6 fiscal year as follows:

7 “(i) \$7,000,000 for fiscal year 2020.

8 “(ii) \$6,000,000 for fiscal year 2021.

9 “(iii) \$7,000,000 for fiscal year 2022.

10 “(iv) \$3,000,000 for fiscal year 2023.

11 “(3) ANNUAL BASE REVENUE.—For purposes
12 of paragraphs (1)(A) and (2)(A), the dollar amount
13 of the annual base revenue for a fiscal year shall
14 be—

15 “(A) for fiscal year 2019, \$8,000,000; and

16 “(B) for fiscal years 2020 through 2023,
17 the dollar amount of the total revenue amount
18 established under this subsection for the pre-
19 vious fiscal year, not including any adjustments
20 made under subsection (c)(2) or (c)(3).

21 “(c) ADJUSTMENTS; ANNUAL FEE SETTING.—

22 “(1) INFLATION ADJUSTMENT.—

23 “(A) IN GENERAL.—For purposes of sub-
24 section (b)(2)(B), the dollar amount of the in-
25 flation adjustment to the annual base revenue

1 for fiscal year 2020 and each subsequent fiscal
2 year shall be equal to the product of—

3 “(i) such annual base revenue for the
4 fiscal year under subsection (b)(2); and
5 “(ii) the inflation adjustment percent-
6 age under subparagraph (C).

7 “(B) OTC MONOGRAPH ORDER REQUEST
8 FEES.—For purposes of subsection (a)(2), the
9 dollar amount of the inflation adjustment to the
10 fee for OTC monograph order requests for fis-
11 cal year 2020 and each subsequent fiscal year
12 shall be equal to the product of—

13 “(i) the applicable fee under sub-
14 section (a)(2) for the preceding fiscal year;
15 and

16 “(ii) the inflation adjustment percent-
17 age under subparagraph (C).

18 “(C) INFLATION ADJUSTMENT PERCENT-
19 AGE.—The inflation adjustment percentage
20 under this subparagraph for a fiscal year is
21 equal to—

22 “(i) for each of fiscal years 2020 and
23 2021, the average annual percent change
24 that occurred in the Consumer Price Index
25 for urban consumers (Washington-Balti-

1 more, DC–MD–VA–WV; Not Seasonally
2 Adjusted; All items; Annual Index) for the
3 first 3 years of the preceding 4 years of
4 available data; and

5 “(ii) for each of fiscal years 2022 and
6 2023, the sum of—

7 “(I) the average annual percent
8 change in the cost, per full-time equiv-
9 alent position of the Food and Drug
10 Administration, of all personnel com-
11 pensation and benefits paid with re-
12 spect to such positions for the first 3
13 years of the preceding 4 fiscal years,
14 multiplied by the proportion of per-
15 sonnel compensation and benefits
16 costs to total costs of OTC mono-
17 graph drug activities for the first 3
18 years of the preceding 4 fiscal years;
19 and

20 “(II) the average annual percent
21 change that occurred in the Consumer
22 Price Index for urban consumers
23 (Washington-Baltimore, DC–MD–VA–
24 WV; Not Seasonally Adjusted; All
25 items; Annual Index) for the first 3

1 years of the preceding 4 years of
2 available data multiplied by the pro-
3 portion of all costs other than per-
4 sonnel compensation and benefits
5 costs to total costs of OTC mono-
6 graph drug activities for the first 3
7 years of the preceding 4 fiscal years.

8 “(2) OPERATING RESERVE ADJUSTMENT.—

9 “(A) IN GENERAL.—For fiscal year 2019
10 and subsequent fiscal years, for purposes of
11 subsections (b)(1)(B) and (b)(2)(C), the Sec-
12 retary may, in addition to adjustments under
13 paragraph (1), further increase the fee revenue
14 and fees if such an adjustment is necessary to
15 provide operating reserves of carryover user
16 fees for OTC monograph drug activities for not
17 more than the number of weeks specified in
18 subparagraph (B).

19 “(B) NUMBER OF WEEKS.—The number of
20 weeks specified in this subparagraph is—

- 21 “(i) 3 weeks for fiscal year 2019;
- 22 “(ii) 7 weeks for fiscal year 2020;
- 23 “(iii) 10 weeks for fiscal year 2021;
- 24 “(iv) 10 weeks for fiscal year 2022;
- 25 and

1 “(v) 10 weeks for fiscal year 2023.

2 “(C) DECREASE.—If the Secretary has
3 carryover balances for such process in excess of
4 10 weeks of the operating reserves referred to
5 in subparagraph (A), the Secretary shall de-
6 crease the fee revenue and fees referred to in
7 such subparagraph to provide for not more than
8 10 weeks of such operating reserves.

9 “(D) RATIONALE FOR ADJUSTMENT.—If
10 an adjustment under this paragraph is made,
11 the rationale for the amount of the increase or
12 decrease (as applicable) in fee revenue and fees
13 shall be contained in the annual Federal Reg-
14 ister notice under paragraph (4) establishing
15 fee revenue and fees for the fiscal year involved.

16 “(3) ADDITIONAL DIRECT COST ADJUST-
17 MENT.—The Secretary shall, in addition to adjust-
18 ments under paragraphs (1) and (2), further in-
19 crease the fee revenue and fees for purposes of sub-
20 section (b)(2)(D) by an amount equal to—

21 “(A) \$14,000,000 for fiscal year 2019;

22 “(B) \$7,000,000 for fiscal year 2020;

23 “(C) \$4,000,000 for fiscal year 2021;

24 “(D) \$3,000,000 for fiscal year 2022; and

25 “(E) \$3,000,000 for fiscal year 2023.

1 “(4) ANNUAL FEE SETTING.—

2 “(A) FISCAL YEAR 2019.—The Secretary
3 shall, not later than the second Monday in
4 March of 2019—

5 “(i) establish OTC monograph drug
6 facility fees for fiscal year 2019 under sub-
7 section (a), based on the revenue amount
8 for such year under subsection (b) and the
9 adjustments provided under this sub-
10 section; and

11 “(ii) publish fee revenue, facility fees,
12 and OTC monograph order requests in the
13 Federal Register.

14 “(B) SUBSEQUENT FISCAL YEARS.—The
15 Secretary shall, not later than the second Mon-
16 day in March of each fiscal year that begins
17 after September 30, 2019—

18 “(i) establish for each such fiscal
19 year, based on the revenue amounts under
20 subsection (b) and the adjustments pro-
21 vided under this subsection—

22 “(I) OTC monograph drug facil-
23 ity fees under subsection (a)(1); and

1 “(II) OTC monograph order re-
2 quest fees under subsection (a)(2);
3 and

4 “(ii) publish such fee revenue
5 amounts, facility fees, and OTC mono-
6 graph order request fees in the Federal
7 Register.

8 “(d) IDENTIFICATION OF FACILITIES.—Each person
9 that owns an OTC monograph drug facility shall submit
10 to the Secretary the information required under this sub-
11 section each year. Such information shall, for each fiscal
12 year—

13 “(1) be submitted as part of the requirements
14 for drug establishment registration set forth in sec-
15 tion 510; and

16 “(2) include for each such facility, at a min-
17 imum, identification of the facility’s business oper-
18 ation as that of an OTC monograph drug facility.

19 “(e) EFFECT OF FAILURE TO PAY FEES.—

20 “(1) OTC MONOGRAPH DRUG FACILITY FEE.—
21 “(A) IN GENERAL.—Failure to pay the fee
22 under subsection (a)(1) within 20 calendar days
23 of the due date as specified in subparagraph
24 (D) of such subsection shall result in the fol-
25 lowing:

1 “(i) The Secretary shall place the fa-
2 cility on a publicly available arrears list.

3 “(ii) All OTC monograph drugs man-
4 ufactured in such a facility or containing
5 an ingredient manufactured in such a facil-
6 ity shall be deemed misbranded under sec-
7 tion 502(ff).

8 “(B) APPLICATION OF PENALTIES.—The
9 penalties under this paragraph shall apply until
10 the fee established by subsection (a)(1) is paid.

11 “(2) ORDER REQUESTS.—An OTC monograph
12 order request submitted by a person subject to fees
13 under subsection (a) shall be considered incomplete
14 and shall not be accepted for filing by the Secretary
15 until all fees owed by such person under this section
16 have been paid.

17 “(3) MEETINGS.—A person subject to fees
18 under this section shall be considered ineligible for
19 OTC monograph drug meetings until all such fees
20 owed by such person have been paid.

21 “(f) CREDITING AND AVAILABILITY OF FEES.—

22 “(1) IN GENERAL.—Fees authorized under sub-
23 section (a) shall be collected and available for obliga-
24 tion only to the extent and in the amount provided
25 in advance in appropriations Acts. Such fees are au-

1 thorized to remain available until expended. Such
2 sums as may be necessary may be transferred from
3 the Food and Drug Administration salaries and ex-
4 penses appropriation account without fiscal year lim-
5 itation to such appropriation account for salaries
6 and expenses with such fiscal year limitation. The
7 sums transferred shall be available solely for OTC
8 monograph drug activities.

9 "(2) COLLECTIONS AND APPROPRIATION
10 ACTS.—

11 "(A) IN GENERAL.—Subject to subparagraph (C), the fees authorized by this section
12 shall be collected and available in each fiscal
13 year in an amount not to exceed the amount
14 specified in appropriation Acts, or otherwise
15 made available for obligation, for such fiscal
16 year.

17 "(B) USE OF FEES AND LIMITATION.—
18 The fees authorized by this section shall be
19 available to defray increases in the costs of the
20 resources allocated for OTC monograph drug
21 activities (including increases in such costs for
22 an additional number of full-time equivalent po-
23 sitions in the Department of Health and
24 Human Services to be engaged in such activi-

1 ties), only if the Secretary allocates for such
2 purpose an amount for such fiscal year (excluding
3 amounts from fees collected under this sec-
4 tion) no less than \$12,000,000, multiplied by
5 the adjustment factor applicable to the fiscal
6 year involved under subsection (c)(1).

7 “(C) COMPLIANCE.—The Secretary shall
8 be considered to have met the requirements of
9 subparagraph (B) in any fiscal year if the costs
10 funded by appropriations and allocated for OTC
11 monograph drug activities are not more than 15
12 percent below the level specified in such sub-
13 paragraph.

14 “(D) PROVISION FOR EARLY PAYMENTS IN
15 SUBSEQUENT YEARS.—Payment of fees author-
16 ized under this section for a fiscal year (after
17 fiscal year 2019), prior to the due date for such
18 fees, may be accepted by the Secretary in ac-
19 cordance with authority provided in advance in
20 a prior year appropriations Act.

21 “(3) AUTHORIZATION OF APPROPRIATIONS.—
22 For each of the fiscal years 2019 through 2023,
23 there is authorized to be appropriated for fees under
24 this section an amount equal to the total amount of
25 fees assessed for such fiscal year under this section.

1 “(g) COLLECTION OF UNPAID FEES.—In any case
2 where the Secretary does not receive payment of a fee as-
3 sessed under subsection (a) within 30 calendar days after
4 it is due, such fee shall be treated as a claim of the United
5 States Government subject to subchapter II of chapter 37
6 of title 31, United States Code.

7 “(h) CONSTRUCTION.—This section may not be con-
8 strued to require that the number of full-time equivalent
9 positions in the Department of Health and Human Serv-
10 ices, for officers, employers, and advisory committees not
11 engaged in OTC monograph drug activities, be reduced
12 to offset the number of officers, employees, and advisory
13 committees so engaged.

14 **“SEC. 744N. REAUTHORIZATION; REPORTING REQUIRE-
15 MENTS.**

16 “(a) PERFORMANCE REPORT.—Beginning with fiscal
17 year 2019, and not later than 120 calendar days after the
18 end of each fiscal year thereafter for which fees are col-
19 lected under this part, the Secretary shall prepare and
20 submit to the Committee on Energy and Commerce of the
21 House of Representatives and the Committee on Health,
22 Education, Labor, and Pensions of the Senate a report
23 concerning the progress of the Food and Drug Adminis-
24 tration in achieving the goals identified in the letters de-
25 scribed in section 2001(b) of the Over-the-Counter Mono-

1 graph Safety, Innovation, and Reform Act of 2019 during
2 such fiscal year and the future plans of the Food and
3 Drug Administration for meeting such goals.

4 “(b) FISCAL REPORT.—Not later than 120 calendar
5 days after the end of fiscal year 2019 and each subsequent
6 fiscal year for which fees are collected under this part,
7 the Secretary shall prepare and submit to the Committee
8 on Energy and Commerce of the House of Representatives
9 and the Committee on Health, Education, Labor, and
10 Pensions of the Senate a report on the implementation
11 of the authority for such fees during such fiscal year and
12 the use, by the Food and Drug Administration, of the fees
13 collected for such fiscal year.

14 “(c) PUBLIC AVAILABILITY.—The Secretary shall
15 make the reports required under subsections (a) and (b)
16 available to the public on the internet website of the Food
17 and Drug Administration.

18 “(d) REAUTHORIZATION.—

19 “(1) CONSULTATION.—In developing rec-
20 ommendations to present to the Congress with re-
21 spect to the goals described in subsection (a), and
22 plans for meeting the goals, for OTC monograph
23 drug activities for the first 5 fiscal years after fiscal
24 year 2023, and for the reauthorization of this part

1 for such fiscal years, the Secretary shall consult
2 with—

3 “(A) the Committee on Energy and Com-
4 merce of the House of Representatives;

5 “(B) the Committee on Health, Education,
6 Labor, and Pensions of the Senate;

7 “(C) scientific and academic experts;

8 “(D) health care professionals;

9 “(E) representatives of patient and con-
10 sumer advocacy groups; and

11 “(F) the regulated industry.

12 “(2) PUBLIC REVIEW OF RECOMMENDA-
13 TIONS.—After negotiations with the regulated indus-
14 try, the Secretary shall—

15 “(A) present the recommendations devel-
16 oped under paragraph (1) to the congressional
17 committees specified in such paragraph;

18 “(B) publish such recommendations in the
19 Federal Register;

20 “(C) provide for a period of 30 calendar
21 days for the public to provide written comments
22 on such recommendations;

23 “(D) hold a meeting at which the public
24 may present its views on such recommenda-
25 tions; and

1 “(E) after consideration of such public
2 views and comments, revise such recommenda-
3 tions as necessary.

4 “(3) TRANSMITTAL OF RECOMMENDATIONS.—
5 Not later than January 15, 2023, the Secretary
6 shall transmit to the Congress the revised rec-
7 ommendations under paragraph (2), a summary of
8 the views and comments received under such para-
9 graph, and any changes made to the recommenda-
10 tions in response to such views and comments.”.

